The blood tests have been heralded by state and federal leaders who hope these so-called antibody tests can help guide decisions about when and how to reopen the country by identifying who has been exposed to the virus and may now have immunity even if they have never been diagnosed.
But in the rush to get tests to the public quickly, there are worries that the Food and Drug Administration (FDA) has allowed companies to market tests with little to no oversight, raising the potential for a surge in inaccurate results. Continue reading.